Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.22 - $0.28 $4,269 - $5,433
19,405 New
19,405 $5,000
Q2 2023

Aug 14, 2023

SELL
$0.22 - $0.55 $6,620 - $16,551
-30,094 Reduced 59.48%
20,501 $6,000
Q1 2023

May 15, 2023

SELL
$0.46 - $1.05 $1,528 - $3,489
-3,323 Reduced 6.16%
50,595 $27,000
Q4 2022

Feb 14, 2023

BUY
$0.89 - $58.2 $18,868 - $1.23 Million
21,201 Added 64.8%
53,918 $47,000
Q3 2022

Nov 14, 2022

BUY
$1.81 - $56.1 $59,217 - $1.84 Million
32,717 New
32,717 $58,000
Q3 2022

Nov 14, 2022

BUY
$1.81 - $56.1 $59,217 - $1.84 Million
32,717 New
32,717 $58,000

Others Institutions Holding GTBP

About GT Biopharma, Inc.


  • Ticker GTBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,557,700
  • Market Cap $96.4M
  • Description
  • GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...
More about GTBP
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.